Disruption of zinc and copper interactions with Aβ(1-40) by a non-toxic, isoniazid-derived, hydrazone: A novel biometal homeostasis restoring agent in Alzheimer's disease therapy?

Metallomics

Volumn 7, Issue 5, 2015, Pages 743-747

  Hauser Davis, R A ^a   De Freitas, L V ^a   Cukierman, D S ^a   Cruz, W S ^a   Miotto, M C ^b   Landeira Fernandez, J ^a   Valiente Gabioud, A A ^b   Fernandez C O ^b   Rey, N A ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Universidad Nacional de Rosario   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; HYDRAZINE;

ABSORPTION PROPERTY; ACUTE TOXICITY; ALZHEIMER'S; ALZHEIMER'S DISEASE; HYDRAZONES; IN-SILICO; NMR TITRATION; NON-TOXIC;

NEURODEGENERATIVE DISEASES;

AMYLOID BETA PROTEIN[1-40]; COPPER; CYTOCHROME P450; GLUTATHIONE; HYDRAZONE DERIVATIVE; ISONIAZID DERIVATIVE; METALLOTHIONEIN; TROMETAMOL; ZINC; AMYLOID BETA PROTEIN; ISONIAZID; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ARTICLE; CHEMICAL INTERACTION; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HOMEOSTASIS; NONHUMAN; OXIDATIVE STRESS; PASSIVE TRANSPORT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; ULTRAVIOLET SPECTROSCOPY; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD BRAIN BARRIER; CHEMISTRY; DRUG EFFECTS; HUMAN; MALE; METABOLISM; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; COPPER; HOMEOSTASIS; HUMANS; HYDRAZONES; ISONIAZID; MALE; PEPTIDE FRAGMENTS; RATS, WISTAR; ZINC;

EID: 84929399907     PISSN: 17565901     EISSN: 1756591X     Source Type: Journal    
DOI: 10.1039/c5mt00003c     Document Type: Article

References (21)

1. R. Mayeux Y. Stern Epidemiology of Alzheimer Disease Cold Spring Harbor Perspect. Med. 2012 2 a006239
2. Alzheimer's. Association, 2014 Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia 2014, 10
3. S. Chen Y. Chen Y. Li S. Chen J. Tan T. Ou L. Gu Z. Huang Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer's disease Bioorg. Med. Chem. 2011 19 5596 5604
4. A. M. Mancino S. S. Hindo A. Kochi M. H. Lim Effects of Clioquinol on Metal-Triggered Amyloid-β Aggregation Revisited Inorg. Chem. 2000 48 9596 9598
5. L. E. Scott C. Orvig Medicinal Inorganic Chemistry Approaches to Passivation and Removal of Aberrant Metal Ions in Disease Chem. Rev. 2009 109 4885 4910
6. A. Budimir Metal ions, Alzheimer's disease and chelation therapy Acta Pharm. 2011 61 1 14
7. K. J. Barnham A. I. Bush Metals in Alzheimer's and Parkinson's diseases Curr. Opin. Chem. Biol. 2008 12 222 228
8. A. Gaeta F. Molina-Holgado X. L. Kong S. Salvage S. Fakih P. T. Francis R. J. Willians R. C. Hiderl Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease Bioorg. Med. Chem. 2011 19 1285 1297
9. L. V. de Freitas C. C. da Silva J. Ellena L. A. Costa N. A. Rey Structural and vibrational study of 8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone-a potential metal-protein attenuating compound (MPAC) for the treatment of Alzheimer's disease Spectrochim. Acta, Part A 2013 116 41 48
10. L. M. Hou H. Y. Shao Y. B. Zhang H. Li N. K. Menon E. B. Neuhaus J. M. Brewer I. J. L. Byeon D. G. Ray M. P. Vitek T. Iwashita R. A. Makula A. B. Przybyla M. G. Zagorski Solution NMR studies of the A beta(1-40) and A beta(1-42) peptides establish that the met35 oxidation state affects the mechanism of amyloid formation J. Am. Chem. Soc. 2004 126 1992 2005
11. Y. Mekmouche Y. Coppel K. Hochgrafe L. Guilloreau C. Tallmard H. Mazarguil P. Faller Characterization of the Zn-ii binding to the peptide amyloid-beta(1-16) linked to Alzheimer's disease ChemBioChem 2005 6 1663 1671
12. C. A. Lipinski F. Lombardo B. W. Dominy P. J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997 23 3 25
13. H. van de Waterbeemd G. Camenisch G. Folkers J. R. Chretien O. A. Raevsky Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors J. Drug Targeting 1998 6 151 165
14. J. Kelder P. D. J. Grootenhuis D. M. Bayada L. P. C. Delbressine J. P. Ploemen Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res. 1999 16 1514 1519
15. L. L. Alvarez H. G. Pardo Guide for the care and use of laboratory animals-Natl-Res-Council Psicothema 1997 9 232 234
16. G. L. Ellman Tissue Sulfhydryl Groups Arch. Biochem. Biophys. 1959 82 70 77
17. M. Erk D. Ivankovi B. Raspor J. Pavicic Evaluation of different purification procedures for the electrochemical quantification of mussel metallothioneins Talanta 2002 57 1211 1218
18. B. Belda-Palazón M. A. Nohales J. L. Rambla J. L. Aceña O. Delgado S. Fustero M. C. Martínez A. Granell J. Carbonell A. Ferrando Biochemical quantitation of the eIF5A hypusination in Arabidopsis thaliana uncovers ABA-dependent regulation Front. Plant Sci. 2014 5 1 11
19. D. R. Conklin K. H. Tan M. Aschner Dimethyl sulfoxide, but not acidosis-induced metallothionein mRNA expression in neonatal rat primary astrocyte cultures is inhibited by the bioflavonoid, quercetin Brain Res. 1998 794 304 308
20. A. Kajal S. Bala N. Sharma S. Kamboj V. Saini Therapeutic Potential of Hydrazones as Anti-Inflammatory Agents Int. J. Med. Chem. 2014 1 11
21. L. M. Gomes R. P. Vieira M. R. Jones M. C. Wang C. Dyrager E. M. Souza-Fagundes J. G. Da Silva T. Storr H. Beraldo 8-Hydroxyquinoline Schiff-base compounds as antioxidants and modulators of copper-mediated Aβ peptide aggregation J. Inorg. Biochem. 2014 139 106 116